Evidence map›Paper›PMID 34337153›Full record

ArticleJournal of scleroderma and related disorders2021

Fatigue Predicts Future Reduced Social Participation, not Reduced Physical Function or Quality of Life in People with Systemic Sclerosis.

Susan L Murphy, Daniel Whibley, Anna L Kratz, Janet L Poole, Dinesh Khanna

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of scleroderma and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02494401 (Taking Charge of Systemic Sclerosis), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02494401 nacompletednot on this map

Taking Charge of Systemic Sclerosis: Improving Patient Outcomes Through Self-management

TypeinterventionalSponsorUniversity of MichiganRan2016 to 2018Enrolled267ConditionsSclerodermaArmsInternet-based self-management program, Scleroderma book
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Understanding the measurement relationship between EQ-5D-5L, PROMIS-29 and PROPr.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Susan L MurphyDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA.
Daniel WhibleyEpidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
Anna L KratzDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA.
Janet L PooleDepartment of Occupational Therapy, University of New Mexico, Albuquerque, New Mexico, USA.
Dinesh KhannaRheumatology Division, Department of Internal Medicine, University of Michigan.
University of Michigan · USUniversity of Aberdeen · GBUniversity of New Mexico · US

Funding

Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
Systemic Sclerosis-Associated Interstitial Lung Disease Response IndexR01AR070470 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2017 to 2019
$642k
Syk blockade in bullous skin diseasesR43AR063129 · NIAMS · PORTOLA PHARMACEUTICALS, INC. · PI SINHA, UMA · 2012 to 2012
$298k
NIAMS NIH HHS K24 AR063120NIAMS NIH HHS R01 AR070470NIAMS NIH HHS R43 AR063129
6 · The paper itself

Abstract

objectiveAlthough fatigue is one of the most problematic symptoms for people with systemic sclerosis, little is known about how fatigue impacts daily life over time. Such information is important when developing fatigue management interventions. This study was conducted to examine 1) if fatigue severity predicted outcomes of worse functioning (social participation, physical function), and quality of life and 2) if level of self-efficacy moderated significant relationships between fatigue and these outcomes.

methodsData were utilized from a clinical trial in which an online self-management intervention was tested (N = 267). Fatigue, social participation, and physical function were assessed by PROMIS measures. Quality of life was assessed by the EuroQol 5-domain instrument (EQ-5D-5L). Linear regressions were performed to examine how baseline fatigue related to functioning and quality of life outcomes 16 weeks later controlling for relevant covariates. PROMIS measures were used to measure self-efficacy in managing symptoms, daily activities, medications and treatments, emotions, and social interactions.

resultsFatigue at baseline significantly predicted social participation 16 weeks later; but did not predict physical functioning or quality of life. Self-efficacy variables did not moderate the association between fatigue and social participation.

conclusionFatigue severity predicted decreased social participation in people with systemic sclerosis. Interventions targeting fatigue should include support to maintain participation of social roles and activities. The level of reported self-efficacy did not vary the strength of the association between fatigue and decline in social participation indicating that there may be other targets to treat fatigue intervention beyond self-management.

trial registrationNCT02494401.

Indexed as

fatigueself-efficacyself-managementsystemic sclerosis

Identifiers

PMID34337153
PMCPMC8320783
OpenAlexW3094092757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.